Current Evidence and Regulatory Guidance from MHRA and EMA Regulatory authorities including the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the European Medicines Agency (EMA) have carefully reviewed available evidence regarding GLP-1 agonists and mental health concerns
SmartPill Motility Capsule A swallowed capsule that tracks GI transit time
In addition to advising patients to wait at least 30 min before taking other oral medications after oral semaglutide, increased clinical and laboratory monitoring should be considered when prescribing medications with a narrow therapeutic index or those that require clinical monitoring, such as levothyroxine [24, 75]
Patients should not discontinue semaglutide without medical guidance, as the back pain is unlikely to be medication-related in most cases
This study, along with other studies involving the PLID, will have a significant impact on the treatment of patients with type-2 diabetes in the future
Some states have implemented step therapy protocols that require trial and failure of lower-cost medications before approving GLP-1 agonists